Effects of CB1 receptor blockade on monosodium glutamate induced hypometabolic and hypothalamic obesity in rats

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 386, Issue 8, 2013, Pages 721-732

  Chen, Wei ^a   Chen, Zhenhua ^a   Xue, Nina ^a   Zheng, Zhibing ^a   Li, Song ^a   Wang, Lili ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

Antagonist; CB1 receptor; Hypometabolic obesity; Hypothalamic obesity; Insulin sensitivity

Indexed keywords

CANNABINOID 1 RECEPTOR; FATTY ACID; GLUTAMATE SODIUM; INSULIN; INSULIN RECEPTOR; RIMONABANT; CANNABINOID RECEPTOR ANTAGONIST; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FATTY LIVER; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHAGIA; HYPOTHALAMUS; INSULIN SENSITIVITY; LIPOGENESIS; LIPOLYSIS; LIVER; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; RAT; RECEPTOR BLOCKING; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG EFFECTS; FEMALE; GLUCOSE INTOLERANCE; HYPERLIPIDEMIAS; INSULIN RESISTANCE; MALE; METABOLISM; NEWBORN; PATHOLOGY; WISTAR RAT;

ADIPOSE TISSUE; ANIMALS; ANIMALS, NEWBORN; CANNABINOID RECEPTOR ANTAGONISTS; FATTY LIVER; FEMALE; GLUCOSE INTOLERANCE; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIVER; MALE; OBESITY; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; RECEPTOR, INSULIN; SODIUM GLUTAMATE;

EID: 84880291632     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0875-y     Document Type: Article

References (46)

1. Bluher M (2006) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 55:908-914
2. Brunetti A, Manfioletti G, Chiefari E, Goldfine ID, Foti D (2001) Transcriptional regulation of human insulin receptor gene by the high-mobility group protein HMGI(Y). FASEB J 15:492-500
3. Chen W, Wang LL, Liu HY, Long L, Li S (2008) Peroxisome proliferator-activated receptor delta-agonist, GW501516, ameliorates insulin resistance, improves dyslipidaemia in monosodium l-glutamate metabolic syndrome mice. Basic Clin Pharmacol Toxicol 637:178-185
4. Chiefari E, Nevolo MT, Arcidiacono B, Maurizio E, Nocera A, Iiritano S, Sgarra R, Possidente K, Palmieri C, Paonessa F, Brunetti G, Manfioletti G, Foti D, Brunetti A (2012) HMGA1 is a novel downstream nuclear target of the insulin receptor signaling pathway. Sci Rep 251:1-10
5. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, Kunos G (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825
6. Dinu R, Popa S, Mota M (2011) The role of the endocannabinoid system in the pathogeny of type 2 diabetes, role of the adipocyte in development of type 2 diabetes, ISBN:978-953-307-598-3, http://www.intechopen.com/books/role-of- theadipocyte
7. Dolnikoff MS, Kater CE, Egami M, de Andrade IS, Marmo MR (1988) Neonatal treatment with monosodium glutamate increases plasma corticosterone in the rat. Neuroendocrinology 48:645-649
8. Elfers C, Ralston M, Roth CL (2011) Studies of different female rat models of hypothalamic obesity. J Pediatr Endocrinol Metab 24:131-137
9. Francisco ME, Seltzman HH, Gilliam AF, Mitchell RA, Rider SL, Pertwee RG, Stevenson LA, Thomas BF (2002) Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole- 3-carboxamide (SR141716). J Med Chem 45:2708-2719
10. Gary-Bobo M (2007) Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 46:122-129
11. Gavin JR III, Roth J, Neville DM Jr, de MP, Buell DN (1974) Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture. Proc Natl Acad Sci USA 71:84-88
12. Gong SL, Xia FQ, Wei J, Li XY, Sun TH, Lu Z, Liu SZ (1995) Harmful effects of MSG on function of hypothalamus-pituitary-target gland system. Biomed Environ Sci 8:310-317
13. Henness S (2006) Rimonabant. Drugs 66:2109-2119
14. Herling AW (2008) Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed Wistar rats. Endocrinology 149:2557-2566
15. Hurrell DG, Pedersen O, Kahn CR (1989) Alterations in the hepatic insulin receptor kinase in genetic and acquired obesity in rats. Endocrinology 125:2454-2462
16. Ioannides-Demos LL, Piccenna L, McNeil JJ (2011) Pharmacotherapies for obesity: past, current, and future therapies. J Obes 2011:179674
17. Jacobson LH, Commerford SR, Gerber SP, Chen YA, Dardik B, Chaperon F, Schwartzkopf C, Nguyen-Tran V, Hollenbeck T, McNamara P, He X, Liu H, Seidel HM, Jaton AL, Gromada J, Teixeira S (2011) Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity. Naunyn Schmiedebergs Arch Pharmacol 384:565-581
18. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, Penarier G, Soubrie P, Le FG, Galiegue S, Casellas P (2005) The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19:1567-1569
19. Jourdan T (2010) CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 59:926-934
20. Kim W, Doyle ME, Liu Z, Lao Q, Shin YK, Carlson OD, Kim HS, Thomas S, Napora JK, Lee EK, Moaddel R, Wang Y, Maudsley S, Martin B, Kulkarni RN, Egan JM (2011) Cannabinoids inhibit insulin receptor signaling in pancreatic beta-cells. Diabetes 60:1198-1209
21. Kim W, Lao Q, Shin YK, Carlson OD, Lee EK, Gorospe M, Kulkarni RN, Egan JM (2012) Cannabinoids induce pancreatic beta-cell death by directly inhibiting insulin receptor activation. Sci Signal 5:ra23
22. Kunos G, Tam J (2011) The case for peripheral CB(1) receptor blockade in the treatment of visceral obesity and its cardiometabolic complications. Br J Pharmacol 163:1423-1431
23. Lee HK, Choi EB, Pak CS (2009) The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents. Curr Top Med Chem 9:482-503
24. Leguisamo NM, Lehnen AM, Machado UF, Okamoto MM, Markoski MM, Pinto GH, Schaan BD (2012) GLUT4 content decreases along with insulin resistance and high levels of inflammatory markers in rats with metabolic syndrome. Cardiovasc Diabetol 11:100
25. Li PP, Shan S, Chen YT, Ning ZQ, Sun SJ, Liu Q, Lu XP, Xie MZ, Shen ZF (2006) The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Br J Pharmacol 148:610-618
26. Macho L, Fickova M, Jezova, Zorad S (2000) Late effects of postnatal administration of monosodium glutamate on insulin action in adult rats. Physiol Res 49(Suppl 1):S79-S85
27. McPartland JM, Glass M, Pertwee RG (2007) Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol 152:583-593
28. Mingorance C (2009) Effects of chronic treatment with the CB1 antagonist, rimonabant on the blood pressure, and vascular reactivity of obese Zucker rats. Obesity 17:1340-1347
29. Miskowiak B, Partyka M (1993) Effects of neonatal treatment with MSG (monosodium glutamate) on hypothalamo-pituitary-thyroid axis in adult male rats. Histol Histopathol 8:731-734
30. Morrison JF, Shehab S, Sheen R, Dhanasekaran S, Shaffiullah M, Mensah-Brown E (2008) Sensory and autonomic nerve changes in the monosodium glutamate-treated rat: a model of type II diabetes. Exp Physiol 93:213-222
31. Nemeroff CB, Lamartiniere CA, Mason GA, Squibb RE, Hong JS, Bondy SC (1981) Marked reduction in gonadal steroid hormone levels in rats treated neonatally with monosodium L-glutamate: further evidence for disruption of hypothalamic-pituitary-gonadal axis regulation. Neuroendocrinology 33:265-267
32. Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschop J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, Fekete C, Reizes O, Rohner-Jeanrenaud F, Tschop MH (2008) Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 57:2977-2991
33. Osei-Hyiaman D (2005) Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115:1298-1305
34. Pan C (2011) Perspectives of CB1 antagonist in treatment of obesity: experience of RIO-Asia. J Obes 2011:957268
35. Parfieniuk A (2008) Role of cannabinoids in chronic liver diseases. World J Gastroenterol 14:6109-6114
36. Ravinet TC, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P (2003) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284:R345-R353
37. Ravinet TC, Delgorge C, Menet C, Arnone M, Soubrie P (2004) CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28:640-648
38. Roth CL (2011) Hypothalamic obesity in patients with craniopharyngioma: profound changes of several weight regulatory circuits. Front Endocrinol (Lausanne) 2:49
39. Roth CL, Blevins JE, Ralston M, Elfers C, Ogimoto K, Kaiyala KJ, Morton GJ (2011) A novel rodent model that mimics the metabolic sequelae of obese craniopharyngioma patients. Pediatr Res 69:230-236
40. Sam AH, Salem V, Ghatei MA (2011) Rimonabant: From RIO to Ban. J Obes 2011:432607
41. Shen JZ, Ma LN, Han Y, Liu JX, Yang WQ, Chen L, Liu Y, Hu Y, Jin MW (2012) Pentamethylquercetin generates beneficial effects in monosodium glutamate-induced obese mice and C2C12 myotubes by activating AMP-activated protein kinase. Diabetologia 55:1836-1846
42. Soli AH, Kahn CR, Neville DM Jr, Roth J (1975) Insulin receptor deficiency in genetic and acquired obesity. J Clin Invest 56:769-780
43. Thornton-Jones ZD, Kennett GA, Benwell KR, Revell DF, Misra A, Sellwood DM, Vickers SP, Clifton PG (2006) The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake. Pharmacol Biochem Behav 84:353-359
44. van Diepen H, Schlicker E, Michel MC (2008) Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716). Naunyn Schmiedebergs Arch Pharmacol 378:345-369
45. Verty AN, Allen AM, Oldfield BJ (2009) The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure. Obesity 17:254-261
46. Zhao W (2010) Genome-wide expression profiling revealed peripheral effects of cannabinoid receptor 1 inverse agonists in improving insulin sensitivity and metabolic parameters. Mol Pharmacol 78:350-359